Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference
October 22, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
Data from Celtaxsys’ Acebilustat Phase 2 Trial addressing Lung Inflammation in CF Patients to be presented at the North American Cystic Fibrosis Conference
October 11, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Full results from the recently completed Phase 2 trial (EMPIRE-CF) of Celtaxsys’ acebilustat will be presented at the North American Cystic Fibrosis...
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
August 02, 2018 08:00 ET
|
Celtaxsys, Inc.
-Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients --Celtaxsys,...
Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July
May 17, 2018 08:00 ET
|
Celtaxsys, Inc.
ATLANTA, May 17, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today...
Akari Therapeutics to Attend Upcoming Investor Conferences in February
January 31, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will...
Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology
November 03, 2016 08:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been...